HIGHLIGHTS
· Revenue reached
· Revenue of Abilify Maintena[®] increased 24% to
· Revenue of Brintellix[®]/Trintellix[®] increased 21% to
· Revenue of Northera[®] increased 19% to
· Revenue of Rexulti[®]/Rxulti[®] increased 35% to
· Revenue of Vyepti[®] reached
· Revenue in
· Revenue in International Markets increased 11% to
· Revenue in
· Revenue of the five strategic brands combined grew by 25% (23% in local currencies), thereby reaching
· In the second quarter both revenue and earnings were negatively impacted by slightly lower demand and destocking related to the ongoing COVID-19 pandemic offsetting the positive effect seen in the first quarter of the year
· Core EBIT reached
· Reported EBIT reached
· Core EPS reached
· The 2020 financial guidance for revenue is maintained at
In connection with the financial report, Lundbeck's President and CEO
"I am very pleased with the results for the first half of the year. COVID-19 is challenging for all societies and for Lundbeck. Our top priority has been to ensure that patients who need our medicines could continue to receive them without interruption and we are proud to have been able to make that happen. The first half performance is encouraging, and the company is strong. We continue to execute on the Expand and Invest to Grow strategy. Vyepti has been launched and despite being significantly impacted by a lower number of medical procedures due to COVID-19, we remain very confident with Vyepti's ability to deliver on its promise based on how it has benefitted the patients treated."
DKK million H1 2020 H1 2019 Growth
Core Revenue* 8,934 8,480 5%
Core EBIT* 2,483 2,729 (9%)
Core EPS* 10.30 10.41 (1%)
Core EBIT margin* 27.8% 32.2% -
Reported Revenue 8,934 8,480 5%
Reported EBIT 1,085 2,305 (53%)
Reported EPS 3.69 8.48 (56%)
Reported EBIT margin 12.1% 27.2% -
*For definition of the measures "Core Revenue", "Core EBIT" and "Core EPS", see note 6 Core reporting
Ottiliavej 9, 2500 Valby,
+45 3630 1311
info@lundbeck.com
https://news.cision.com/h--lundbeck-a-s/r/strong-momentum-across-all-strategic-brands-with-25--growth-in-the-first-half-of-2020,c3167934
https://mb.cision.com/Main/18215/3167934/1290494.pdf
(c) 2020 Cision. All rights reserved., source